StocksDeepDive
Snapshot · Russell 3000 · generated 2026-10-17 22:05 UTC

SRPT — Sarepta Therapeutics, Inc.

EXPENSIVE (MOS Model unreliable) · Quality 47/100

Price
17.1
Intrinsic value
3.38
Margin of safety
Model unreliable
Implied growth (reverse DCF)
+36.8%
model assumes +5.5%
Value Score
11.5
Quality
47
Psychology
26.3
Discovery
35.9
price/volume attention only
Moat score
0
erosion: none

Value Score: bottom 14% of Russell 3000 · Quality: bottom 35%

Open the interactive Deep Dive for SRPT →

Use this data programmatically

This page's numbers are also available as JSON at /api/v1/deep-dive/SRPT - see the API docs for the full read-only surface, including an MCP server for AI assistants.

Common questions

Is SRPT undervalued?

As of 2026-10-17, SRPT trades at 17.1 against a computed intrinsic value of 3.38 (-406.6% margin of safety) - StocksDeepDive's valuation label for this is EXPENSIVE. This is a described calculation from public data, not a recommendation.

What is Sarepta Therapeutics, Inc.'s Value Score?

Sarepta Therapeutics, Inc.'s Value Score is 11.5 as of 2026-10-17 - it combines value, quality, crowd psychology and market attention into one number.